One weekend statement says the first Ebola hot spots in Congo are under control. The head of Africa CDC says the outbreak as a whole is not. Both can be true. You're listening to Ebola Watch, and it's Monday, November 16th. First, the six-month assessments released on Sunday, plus the newest confirmed count. Then vaccines: two candidates designed for Bundibugyo are headed into Congo's trial, and WHO's vaccine advisers meet tomorrow.
From WHO's Africa office, in a joint statement with Africa CDC, UNICEF, UNFPA and the World Food Programme:
While the response has slowed transmission in the initial epicentres, 400 to 500 new cases continue to be reported each week, and the outbreak has expanded to 67 health zones in eight provinces.
So which is it, progress or a crisis that's still growing? The statement claims both. It says rapid transmission has been halted in most of the early epicentres, naming Mongbwalu, Nyankunde, Nizi, Rwampara and Butembo. In Bunia, new cases have halved. Testing has grown from two laboratories to more than two dozen, and around 3,000 people have recovered. And the other column? Contact follow-up remains below target. Two-thirds of confirmed deaths are happening in communities, which the agencies read as infections being identified too late. Children account for more than a quarter of confirmed cases and a third of deaths, and seven in ten children under five with confirmed Ebola have died. Seven in ten. That's the figure people should hear. Then there's Jean Kaseya, Africa CDC's director-general, who spoke to Reuters on Sunday. He said the outbreak is still serious and still not under control. According to him, more than 80 percent of new cases are turning up among people who weren't on any contact list. His agency co-signed the joint statement, so read it as a difference in emphasis, not a contradiction. Where does the count stand? The AFREEQUE newsroom, compiling the health ministry's situation report, gives 11,376 confirmed cases and 5,568 deaths as of Saturday, November 14th, with 456 new confirmed cases in the last seven days. On Friday we cited 11,114 confirmed as of November 10th. The statement also reports a second attack on Cantine-Aloya early on November 11th and more than 80 attacks on health care since the outbreak was declared, and it calls for a halt in hostilities. And the money, because I keep hearing very different numbers. You are. Kaseya says about 2.9 billion dollars has been pledged, and he wants donors to release around 1.6 billion of it. Meanwhile, according to Actualité.cd via AFREEQUE, health minister Samuel Roger Kamba told lawmakers on November 10th that he couldn't confirm the 700-million-dollar-plus figure Kaseya had cited, because partner money goes straight to the agencies doing the work. One loose end from Friday: Nigeria. We still haven't seen confirmation that Nigeria's last contacts finished monitoring. The most recent figures, from an NCDC update reported November 11th, were 34 of 62 contacts finished, 28 still being watched, and no additional case.
Moses Kibwana, writing for Willow Health Media:
That gap may now narrow as two vaccine candidates developed specifically to protect against the Bundibugyo species of Ebola are set to join the ongoing Tumaini clinical trial in the DRC. It will be the first time vaccines designed for Bundibugyo virus are tested during an outbreak of the disease.
Wait, isn't Tumaini already underway? Since late October in Bunia, with Ervebo, which is licensed against the Zaire species but unproven against Bundibugyo. The two newcomers are ChAdOx1, from the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469. WHO announced the decision on November 4th, on the advice of its Technical Advisory Group on Candidate Vaccine Prioritization. Gavi says early trials in the United Kingdom and Canada suggest both can safely stimulate immune responses. So when do actual doses go out? Once national approvals come through, and the article doesn't give a date. Kibwana also stresses that being in the trial doesn't prove the vaccines work or make them approved for public use. Separately, Kenya's Director General for Health, Patrick Amoth, said last Wednesday that IAVI has 36 million dollars to start a vaccine trial in Kenya in January 2027. So the purpose-built vaccines are months off. That's exactly MSF's complaint. It is. We covered MSF's call on November 10th to lift the research-only limits on Ervebo, and The Hindu BusinessLine ran that statement again this weekend. Semafor reports Congo asked for 500,000 doses and got 70,000. For now WHO recommends restricting Ervebo against Bundibugyo to research studies because its effect is unproven. A bigger release from the global stockpile would need backing from WHO's vaccine advisers, known as SAGE, and they meet tomorrow, Tuesday the 17th.
A small favor before we go. If Ebola Watch helps you keep this outbreak straight, rate us or write a line or two in your podcast app. That's how other listeners find a show like this.
Tomorrow we'll look for anything that comes out of the SAGE meeting on Ervebo, and for a final word on Nigeria's contacts. Thanks for starting your week with us. Ebola Watch is made by Lantern Podcasts, and we'll talk tomorrow.